Hormone Therapy and Receptor Studies in Human Renal Cell Carcinoma

  • G. Pizzocaro
  • Lombardy Study Group
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 53)


There is very clear experimental evidence of the hormone-dependence of renal cancer in the male hamster (1–5) but little evidence of the effectiveness of hormone therapy in humans. Opinions are controversial and Hrushesky & Murphy (6) pointed out that the cumulative reported response rate to either progesterone or androgen therapy in advanced renal cell carcinoma was 17% in the literature up to 1971 and less than 2% afterwards. In recent years, antiestro-gens have been tried and the response rate reported in the largest published series (7) is 4% objective remission and 28% subjective improvement. Different criteria of evaluation may be responsible for the widely differing results reported in the older literature.


Renal Cell Carcinoma Renal Cancer Renal Carcinoma Syrian Hamster Neoplastic Tissue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    H.J.G. Bloom, G.E. Dukes, and B.C.V. Mitchley, Hormone-dependent tumours of the kidney, Br. J. Cancer 17: 611 (1963).PubMedCrossRefGoogle Scholar
  2. 2.
    H. Kirkman, Estrogen induced tumours of the kidney in the Syrian hamster, Nat. Cancer Inst. Monogr. 1: 1 (1959).PubMedGoogle Scholar
  3. 3.
    J.J. Li, D.J. Talley, S.A. Li, and C.A. Villee, Receptor characteristic of specific estrogen binding in the renal adenocarcinoma of the golden hamster, Cancer Res. 36: 1127 (1976).PubMedGoogle Scholar
  4. 4.
    J.J. Li, T.L. Curthbertson, and S.A. Li, Specific androgen binding in the kidney and estrogen-dependent renal carcinoma of the Syrian hamster, Endrocrinology 101: 1006 (1977).CrossRefGoogle Scholar
  5. 5.
    S.A. Li and J.J. Li, Estrogen-induced progesterone receptor in the Syrian hamster kidney. I. Modulation by antiestrogens and androgens, Endocrinology 103: 2119 (1978).PubMedCrossRefGoogle Scholar
  6. 6.
    W.J. Hrushesky and G.P. Murphy, Current status of the therapy of advanced renal carcinoma, J. Surg. Oncol. 9: 277 (1977).PubMedCrossRefGoogle Scholar
  7. 7.
    M. Al-Sarraf, The clinical trial of Tamoxifen in patients with advanced renal cell cancer in South West Oncology Group Study, Proc. Am. Assoc. Cancer Res. 20: 378 (1979).Google Scholar
  8. 8.
    G. Concolino, A. Marocchi, C. Conti, R. Tenaglia, F. Di Silverio, and U. Bracci, Human renal cell carcinoma as a hormone-dependent tumor, Cancer Res. 38: 4340 (1978).PubMedGoogle Scholar
  9. 9.
    G. Concolino, F. Di Silverio, A. Marocchi, and U. Bracci, Renal cancer steroid receptors: Biochemical basis for endocrine therapy, Eur. Urol. 5: 90 (1979).PubMedGoogle Scholar
  10. 10.
    H. Bojar, R. Dreyfürst, K. Balzer, W. Staib, and J.C. Wittliff, Oestrogen-binding components in human renal cell carcinoma, J. Clin. Chem. Clin. Biochem. 14: 521 (1976).PubMedGoogle Scholar
  11. 11.
    H. Bojar, K. Maar, and W. Staib, The endocrine background of human renal cell carcinoma — I — Binding of the highly potent progestin R 5020 by tumor cytosol, Urol. Int. 34: 302 (1979).PubMedCrossRefGoogle Scholar
  12. 12.
    H. Bojar, K. Maar, and W. Staib, The endocrine background of human renal cell carcinoma. II. Attempt to induce the R 5020 binding components by oestrogens, Urol. Int. 34: 311 (1979).Google Scholar
  13. 13.
    G.P. Hemstreet, J.L. Wittliff, A.M. Sariff, M.C. Hall, L.J. McRae, and J.R. Durant, Comparison of steroid receptor levels in renal cell carcinoma and autologous normal kidney, Int. J. Cancer 26: 769 (1980).PubMedCrossRefGoogle Scholar
  14. 14.
    H. Bojar, K. Maar, and W. Staib, The endocrine background of human renal cell carcinoma. IV. Glucocorticoid receptors as possible mediators of progesterone action, Urol. Int. 34: 330 (1979).PubMedCrossRefGoogle Scholar
  15. 15.
    H. Bojar, K. Maar, and W. Staib, The endocrine background of human renal cell carcinoma. V. Binding of the highly potent androgen methyltrienolone (R1881) by tumour cytosol, Urol. Int. 35: 154 (1980).PubMedCrossRefGoogle Scholar
  16. 16.
    L. Chen, F.R. Weiss, S. Chaichik, and I. Keydar, Steroid receptors in human renal carcinoma, Isr. J. Med. Sci. 16: 756 (1980).PubMedGoogle Scholar
  17. 17.
    M.E. Rapertin-Oblin, C. Roth-Mayer, M. Claire, A. Michaud, E. Baviera, J.M. Brisset, and P. Corvol, Are mineral corticoid receptors present in human renal adenocarcinoma? Clin. Sci. 57: 421 (1979).Google Scholar
  18. 18.
    G. Di Fronzo, E. Ronchi, F. Bertuzzi, P. Vezzoni, and G. Pizzocaro, Estrogen receptors in renal carcinoma, Eur. Urol. 6: 307 (1980).PubMedGoogle Scholar
  19. 19.
    G. Pizzocaro, M. Valente, I. Cataldo, P. Vezzoni, and G. Di Fronzo, Estrogen receptors and MPA treatment in metastatic renal carcinoma. A preliminary report. Tumori 66: 739 (1980).PubMedGoogle Scholar
  20. 20.
    M. Namer, C. Lalanne, and E.E. Baulieu, Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer, Cancer Res. 40: 1750 (1980).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • G. Pizzocaro
    • 1
  • Lombardy Study Group
  1. 1.Istituto Nazionale TumoriMilanItaly

Personalised recommendations